A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults With Chronic Coronary Syndrome

Key Inclusion Criteria: * Chronic coronary syndrome participants defined by the presence of any of the following conditions: * History of coronary artery disease with coronary artery stenosis confirmed by a coronary catheterization (at any time prior to Screening) / computed tomography (CT) angiogram ≥ 50%. * Previously documented myocardial infarction occurring more than 3 months prior to Screening. * Acetylsalicylic acid as mono antiplatelet background therapy stable for at least 1 month prior to Screening. * Minimum weight of 50.0 kg at Screening. Key Exclusion Criteria: * Known liver impairment significantly affecting the hepatic function (e.g., ascites, icterus, signs of coagulopathy). * End-stage renal failure requiring dialysis. * Treatment with another investigational small-molecule or peptide drug within 3 months or 5 × t1/2 (whichever is longer) or with an investigational antibody treatment within 6 months prior to Screening. * History of major medical or surgical disorders, which in the opinion of the investigator, are likely to interfere with the metabolism, or excretion of the trial treatment(s) (appendectomy and herniotomy allowed). * Concomitant diseases (e.g., advanced liver cirrhosis, mental illness, neurodegenerative disease, terminal malignancy, etc.) or conditions (e.g., inability to communicate well with the investigator in the local language, inability to consent) that, in the opinion of the investigator, may prevent subject from complying with s…